Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

A Study Designed to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD4954 and the Absolute Bioavailability of AZD4954

4 september 2026 bijgewerkt door: AstraZeneca

An Open-Label Study to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD4954 and Absolute Bioavailability of AZD4954 in Healthy Male Participants

This study in healthy volunteers aims to explore blood levels and side effects of the test medicine, and look at how it is broken down when injected into a vein or given as a liquid by mouth. The test medicine will be radiolabelled with a small amount of carbon-14 so it can be tracked in the body.

This two-part study will take place at one site in Nottingham, United Kingdom, and will enroll 8 healthy men in each part, aged 30-65 years.

Studie Overzicht

Toestand

Nog niet aan het werven

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

This study in healthy volunteers aims to explore blood levels and side effects of the test medicine, and look at how it is broken down when injected into a vein or given as a liquid by mouth. The test medicine will be radiolabelled with a small amount of carbon-14 so it can be tracked in the body.

This study will take place at one site in Nottingham, United Kingdom.

It is planned to enroll 8 healthy male participants in each part, aged 30-65 years.

In part 1 volunteers will receive a single dose of radiolabelled test medicine as a liquid by mouth. They'll stay in the clinic for up to 24 nights, attend 1 outpatient visit, and take up to 8 weeks to finish the study.

In part 2 volunteers will receive a single dose of test medicine by mouth and, shortly afterwards, a very tiny dose of radiolabelled study medicine by injection into a vein. They'll stay in the clinic for up to 15 nights, attend 1 outpatient visit, and take up to 7 weeks to finish the study.

Blood and urine samples will be collected to do safety tests. Blood, urine and faecal samples will be collected to measure the amount of test medicine and its breakdown products.

Studietype

Ingrijpend

Inschrijving (Geschat)

16

Fase

  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Ja

Beschrijving

Inclusion Criteria:

  • Healthy males aged 30 to 65 years inclusive
  • BMI of 18.0 to 35.0 kg/m2 inclusive
  • Regular bowel movements (i.e. average stool production of ≥1 and ≤3 stools per day)

Exclusion Criteria:

  • Serious adverse reaction or serious hypersensitivity to any drug or formulation excipients
  • Presence or history of clinically significant allergy requiring treatment
  • History of clinically significant cardiovascular, renal, hepatic, respiratory, dermatological or gastrointestinal disease, and neurological or psychiatric disorder
  • History of cholecystectomy or gall stones
  • History of GI surgery
  • Acute diarrhoea or constipation in the 7 days before the predicted Day 1
  • Participants who do not have suitable veins for multiple venepunctures/cannulation
  • Clinically significant abnormal clinical chemistry, haematology, coagulation or urinalysis
  • Evidence of renal impairment at screening
  • Participants who have received any IMP in a clinical research study within the 90 days prior to Day 1
  • Participants who have previously been administered IMP in this study
  • Radiation exposure exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years
  • Participants who have been administered IMP in an ADME study in the last 12 months
  • Donation of blood or plasma within the previous 3 months or loss of greater than 400 mL of blood
  • Use of any prescribed or non-prescribed medication including antacids, gastric pH modifying agents, analgesics, herbal remedies, vitamins and minerals within 2 weeks of dosing
  • Current smokers or known or suspected history of alcohol or drug abuse
  • Excessive intake of caffeine-containing drinks or food

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Niet-gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Part 1
Participants in Part 1 will receive a single dose of [14C]AZD4954 Oral Solution.
Geneesmiddel: [14C]AZD4954 Oral Solution
Participants in Part 1 will recieve a single dose of [14C]AZD4954 oral solution
Experimenteel: Part 2
Participants in Part 2 will receive a single unlabelled oral dose of AZD4954 tablet and a radiolabelled IV microtracer dose of [14C]AZD4954.
Geneesmiddel: AZD4954 film-coated tablet
Participants in Part 2 will receive a single dose of AZD4954 film-coated tablet by mouth
Geneesmiddel: [14C]AZD4954 Solution for Infusion
Participants in Part 2 will receive a single very tiny dose of radiolabelled [14C]AZD4954 Solution for Infusion as a slow injection into a vein

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Amount of AZD4954 excreted (Ae) (Part 1)
Tijdsspanne: Urine and faecal samples collected from pre-dose until up to 552 hours post-dose
Mass balance recovery, rates and routes of elimination of total radioactivity of [14C] AZD4954 in urine, faeces and all excreta
Urine and faecal samples collected from pre-dose until up to 552 hours post-dose
Amount of AZD4954 excreted expressed as a fraction of dose excreted (Fe) (Part 1)
Tijdsspanne: Urine and faecal samples collected from pre-dose until up to 552 hours post-dose
Mass balance recovery, rates and routes of elimination of total radioactivity of [14C] AZD4954 in urine, faeces and all excreta
Urine and faecal samples collected from pre-dose until up to 552 hours post-dose
Cumulative amount of AZD4954 excreted (CumAe) (Part 1)
Tijdsspanne: Urine and faecal samples collected from pre-dose until up to 552 hours post-dose
Mass balance recovery, rates and routes of elimination of total radioactivity of [14C] AZD4954 in urine, faeces and all excreta
Urine and faecal samples collected from pre-dose until up to 552 hours post-dose
Cumulative amount of AZD4954 excreted expressed as a fraction of dose excreted (CumFe) (Part 1)
Tijdsspanne: Urine and faecal samples collected from pre-dose until up to 552 hours post-dose
Mass balance recovery, rates and routes of elimination of total radioactivity of [14C] AZD4954 in urine, faeces and all excreta
Urine and faecal samples collected from pre-dose until up to 552 hours post-dose
Absolute bioavailability (F) based on AUC0-inf (Part 2)
Tijdsspanne: Plasma, urine and faecal samples from pre-dose until up to 336 hours post-dose
Absolute bioavailability of AZD4954 oral and IV administration, adjusted for dose
Plasma, urine and faecal samples from pre-dose until up to 336 hours post-dose

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Maximum observed concentration (Cmax) for AZD4954 and total radioactivity (Parts 1 and 2)
Tijdsspanne: Plasma, urine, and whole blood samples collected from pre-dose until up to 552 hours post-dose
The PK of AZD4954 and [14C]AZD4954 in plasma and urine, and total radioactivity in plasma and whole blood
Plasma, urine, and whole blood samples collected from pre-dose until up to 552 hours post-dose
Time of maximum observed concentration (Tmax) for AZD4954 and total radioactivity (Parts 1 and 2)
Tijdsspanne: Plasma, urine, and whole blood samples collected from pre-dose until up to 552 hours post-dose
The PK of AZD4954 and [14C]AZD4954 in plasma and urine, and total radioactivity in plasma and whole blood
Plasma, urine, and whole blood samples collected from pre-dose until up to 552 hours post-dose
Area under the curve from time 0 extrapolated to infinity (AUC0-inf) for AZD4954 and total radioactivity (Parts 1 and 2)
Tijdsspanne: Plasma, urine, and whole blood samples collected from pre-dose until up to 552 hours post-dose
The PK of AZD4954 and [14C]AZD4954 in plasma and urine, and total radioactivity in plasma and whole blood
Plasma, urine, and whole blood samples collected from pre-dose until up to 552 hours post-dose
Terminal elimination half-life (T1/2) for AZD4954 and total radioactivity (Parts 1 and 2)
Tijdsspanne: Plasma, urine, and whole blood samples collected from pre-dose until up to 552 hours post-dose
The PK of AZD4954 and [14C]AZD4954 in plasma and urine, and total radioactivity in plasma and whole blood
Plasma, urine, and whole blood samples collected from pre-dose until up to 552 hours post-dose
Area under the curve (AUC) of circulating total radioactivity accounting for 10% or more of the dose (Part 1)
Tijdsspanne: Plasma, urine and faecal samples collected from pre-dose until up to 552 hours post-dose
Identification of the chemical structure of each metabolite
Plasma, urine and faecal samples collected from pre-dose until up to 552 hours post-dose
80% or more of the radioactivity recovered in excreta (Part 1)
Tijdsspanne: Plasma, urine and faecal samples collected from pre-dose until up to 552 hours post-dose
Identification of the chemical structure of each metabolite
Plasma, urine and faecal samples collected from pre-dose until up to 552 hours post-dose
Disposition of total radioactivity in plasma and in blood (Part 1)
Tijdsspanne: Plasma, and whole blood samples collected from pre-dose until up to 552 hours post-dose
Evaluation of whole blood:plasma concentration ratios for total radioactivity
Plasma, and whole blood samples collected from pre-dose until up to 552 hours post-dose

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

AstraZeneca

Medewerkers

Quotient Sciences

Onderzoekers

  • Hoofdonderzoeker: Sharan Sidhu, MBChB, BAO, MRCS, MFPM, Quotient Sciences

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

19 oktober 2026

Primaire voltooiing (Geschat)

17 december 2026

Studie voltooiing (Geschat)

17 december 2026

Studieregistratiedata

Eerst ingediend

4 september 2026

Eerst ingediend dat voldeed aan de QC-criteria

4 september 2026

Eerst geplaatst (Werkelijk)

10 september 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

10 september 2026

Laatste update ingediend die voldeed aan QC-criteria

4 september 2026

Laatst geverifieerd

1 augustus 2026

Meer informatie

Termen gerelateerd aan deze studie

Trefwoorden

Andere studie-ID-nummers

  • D7300C00005

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

IPD-tijdsbestek voor delen

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment athttps://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD-toegangscriteria voor delen

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environmentVivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren